Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record.

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

Clanet, M., Radue, E.W., Kappos, L., Hartung, H.P., Hohlfeld, R., Sandberg-Wollheim, M., Kooijmans-Coutinho, M.F., Tsao, E.C., Sandrock, A.W., the European IFNβ-1a (Avonex) Dose-Comparison Study Investigators*·2002·Neurology

Abstract

BACKGROUND: Interferon beta-1a (IFNbeta-1a; Avonex) is effective for the treatment of relapsing MS; however, the optimal dose of IFNbeta-1a is not known. OBJECTIVE: To determine whether IFNbeta-1a 60 micro g IM once weekly is more effective than IFNbeta-1a 30 micro g IM once weekly in reducing disability progression in relapsing MS. METHODS: In a double-blind, parallel-group, dose-comparison study, 802 patients with relapsing MS from 38 centers in Europe were randomized to IFNbeta-1a 30 micro g (n = 402) or 60 micro g (n = 400) IM once weekly for >/=36 months. The primary endpoint was disability progression, defined as time to a sustained increase of >/=1.0 point on the Expanded Disability Status Scale (EDSS) persisting for 6 months. Additional endpoints included relapses, MRI, safety, immunogenicity, and subgroup analyses of disability progression. RESULTS: Both groups showed equal rates of disability progression (hazard ratio, 0.96; 95% CI, 0.77 to 1.20; p = 0.73). In both groups the proportion of subjects with progression of disability by 36 months estimated from Kaplan-Meier curves was 37%. No dose effects were observed on any of the secondary clinical endpoints. Only one MRI measure at one time point, number of new or enlarging T2 lesions at month 36 compared with month 24, showed a difference favoring the 60- micro g dose. Both doses were well tolerated; however, slightly higher incidences of flulike symptoms and muscle weakness were observed in the 60- micro g group. The incidences of neutralizing antibodies (titers >/= 20) were 2.3% in the 30- micro g group and 5.8% in the 60- micro g group. CONCLUSION: There was no difference between IFNbeta-1a 30 micro g and 60 micro g IM in clinical or MRI measures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000032256.35561.d6

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 220

Metadata

Authors
Clanet, M., Radue, E. W., Kappos, L., Hartung, H. P., Hohlfeld, R., Sandberg-Wollheim, M., Kooijmans-Coutinho, M. F., Tsao, E. C., Sandrock, A. W., & the European IFNβ-1a (Avonex) Dose-Comparison Study Investigators*
Venue
Neurology
Published
2002-11-26
Volume
59
Issue
10
Pages
1507-1517
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2168301183
Cited by
220
References
0
FWCI
13.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. https://app.cochat.ai/papers/10.1212/01.wnl.0000032256.35561.d6
The paper
Clanet, M., Radue, E. W., Kappos, L., Hartung, H. P., Hohlfeld, R., Sandberg-Wollheim, M., Kooijmans-Coutinho, M. F., Tsao, E. C., Sandrock, A. W., & the European IFNβ-1a (Avonex) Dose-Comparison Study Investigators*. (2002). A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology. https://doi.org/10.1212/01.wnl.0000032256.35561.d6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.